 |
Nov 6, 2008
Threshold Pharmaceuticals Reports Third Quarter 2008 Financial Results |
| |
REDWOOD CITY, Calif., Nov 6, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2008. The net loss for the third quarter of 2008 was $4.6 million compared to $6.6 million for the third quarter of 2007.
Research and development e...
|
|
Nov 5, 2008
Threshold to Present At Rodman & Renshaw Healthcare Conference |
| |
REDWOOD CITY, Calif., Nov 5, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it will present at the Rodman & Renshaw 10th Annual Healthcare Conference at the New York Palace Hotel in New York City.
Threshold's CEO, Barry Selick, Ph.D., will present at 11:35 a.m. Eastern Time on...
|
|
Oct 22, 2008
Threshold Pharmaceuticals Presents Encouraging Additional Preliminary Findings From a Phase 1 Clinical Trial of TH-302 for Solid Tumors |
| |
REDWOOD CITY, Calif., Oct 22, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced two presentations on its clinical stage hypoxia-activated prodrug, TH-302. The first is the Boston Biotech R&D Conference held today at the Harvard Medical School in Boston. The second is the European Organisat...
|
|
Oct 13, 2008
Threshold Pharmaceuticals Provides Clarification on Common Shares Outstanding Following Recent Private Placement |
| |
REDWOOD CITY, Calif., Oct 13, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) announced today a clarification for shareholders regarding the current number of common shares outstanding.
On August 29, 2008 the Company announced the completion of a private placement that increased the number of common...
|
|
Sep 16, 2008
Threshold Pharmaceuticals Initiates a Clinical Trial Evaluating TH-302 in Patients With Soft Tissue Sarcoma |
| |
REDWOOD CITY, Calif., Sep 16, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that it has initiated a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifica...
|
|
Sep 9, 2008
Threshold Pharmaceuticals Achieves Compliance With NASDAQ Minimum Bid Price Rule |
| |
REDWOOD CITY, Calif., Sep 9, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), announced today that it has received written communication from the NASDAQ Listing Qualifications Panel that the Company has demonstrated compliance with NASDAQ's Minimum Bid Price Requirement, as evidenced by a closing bid p...
|
|
Sep 2, 2008
Threshold Pharmaceuticals Completes $18 Million Private Equity Financing |
| |
REDWOOD CITY, Calif., Sep 2, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that its previously announced private placement of Threshold common stock and warrants received shareholder approval and has been completed. Threshold sold 8,970,574 shares of its common stock at $2.04 per sha...
|
|
Aug 20, 2008
Threshold Pharmaceuticals Announces Reverse Stock Split |
| |
REDWOOD CITY, Calif., Aug 20, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD) today announced the effectiveness of a reverse stock split. Effective today, every six shares of the Company's common stock will be combined into one share of common stock; holders of fractional shares created by the reverse ...
|
|
Aug 12, 2008
Threshold Pharmaceuticals Initiates a Second Clinical Trial Evaluating TH-302 in Patients With Solid Tumors |
| |
REDWOOD CITY, Calif., Aug 12, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a clinical trial of TH-302 in combination with various chemotherapeutic agents in patients with advanced solid tumors. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifi...
|
|
Aug 7, 2008
Threshold Pharmaceuticals Reports Second Quarter 2008 Financial Results |
| |
REDWOOD CITY, Calif., Aug 7, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the second quarter ended June 30, 2008.
The net loss for the second quarter of 2008 was $4.0 million compared to $7.6 million for the second quarter of 2007. Research and development exp...
|
|
Jul 24, 2008
Dr. Herbert Hurwitz Joins Scientific Advisory Board At Threshold |
| |
REDWOOD CITY, Calif., Jul 24, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that Herbert Hurwitz, M.D. has joined the Company's Scientific Advisory Board (SAB). Dr. Hurwitz is an Associate Professor of Medicine at Duke University Medical Center and a medical oncologist at the Duke Com...
|
|
Jul 22, 2008
Threshold Pharmaceuticals Presents Encouraging Interim Results From a Phase 1 Clinical Trial of TH-302 for Solid Tumors At AACR Conference On Translational Medicine |
| |
REDWOOD CITY, Calif., Jul 22, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine: Cancer Clinical Trials and ...
|
|
Jul 10, 2008
Threshold Pharmaceuticals Announces $18 Million Private Equity Financing |
| |
REDWOOD CITY, Calif., Jul 10, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that it has entered into a purchase agreement with a select group of investors that includes Sutter Hill Ventures, HealthCare Ventures, LLC, Alta Partners and Three Arch Partners in connection with a proposed s...
|
|
Jun 16, 2008
Threshold Pharmaceuticals' Request to Transfer to NASDAQ Capital Market Approved |
| |
REDWOOD CITY, Calif., Jun 16, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (THLD) today announced that it has received approval from the NASDAQ Listing Qualifications Panel (the Panel) to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market. The transfer will be effec...
|
|
May 7, 2008
Threshold Pharmaceuticals Reports First Quarter 2008 Financial Results |
| |
REDWOOD CITY, Calif., May 7, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the first quarter ended March 31, 2008.
The net loss for the first quarter of 2008 was $5.0 million compared to $9.1 million for the first quarter of 2007. Research and development expen...
|
|
Apr 18, 2008
Threshold Pharmaceuticals Received Anticipated NASDAQ Staff Determination Letter |
| |
REDWOOD CITY, Calif., Apr 18, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that on April 17, 2008, it received a Staff Determination Letter from NASDAQ indicating that the Company has not gained compliance with the $1.00 minimum bid price requirement for continued listing on the NASDA...
|
|
Apr 14, 2008
Multiple Presentations On Oncology Pipeline At the 2008 American Association for Cancer Research Annual Meeting |
| |
REDWOOD CITY, Calif., Apr 14, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced three presentations regarding its hypoxia-activated prodrug (HAP) platform, which includes the lead HAP candidate, TH-302. The presentations took place on Sunday, April 13 at the 2008 American Association for C...
|
|
Apr 11, 2008
Threshold Pharmaceuticals Announces Multiple Presentations On Oncology Pipeline At the 2008 American Association for Cancer Research Annual Meeting |
| |
REDWOOD CITY, Calif., Apr 11, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced multiple presentations regarding its oncology pipeline, which includes three preclinical presentations on its hypoxia-activated prodrugs. TH-302, the lead hypoxia-activated prodrug, began a Phase 1 clinical tri...
|
|
Mar 6, 2008
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2007 Financial Results |
| |
REDWOOD CITY, Calif., Mar 6, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the fourth quarter and the year ended December 31, 2007.
The net loss for 2007 was $30.7 million compared to a net loss of $55.7 million in 2006. Total research and development expenses ...
|
|
Feb 11, 2008
Threshold Pharmaceuticals to Present At BIO CEO & Investor Conference |
| |
REDWOOD CITY, Calif., Feb 11, 2008 (PrimeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that Barry Selick, chief executive officer of Threshold, will present at the BIO CEO & Investor Conference on Wednesday, February 13, 2008 at 2:00 p.m. ET. Dr. Selick will provide a general update on the Compa...
|
|
|
